Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Soriano

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Entropy (Basel, Switzerland)|May 16, 2023
How Well Can We Infer Selection Benefits and Mutation Rates from Allele Frequencies?Jonathan Soriano, Sarah Marzen
Scientific Reports|September 29, 2021
Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cellsRonald D Seidel, Zohra Merazga, Dharma Raj Thapa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven MalignanciesSteven N Quayle, Natasha Girgis, Dharma R Thapa, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Entropy (Basel, Switzerland)|May 16, 2023
How Well Can We Infer Selection Benefits and Mutation Rates from Allele Frequencies?Jonathan Soriano, Sarah Marzen
Scientific Reports|September 29, 2021
Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cellsRonald D Seidel, Zohra Merazga, Dharma Raj Thapa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven MalignanciesSteven N Quayle, Natasha Girgis, Dharma R Thapa, et al.
Pageof 1